<DOC>
	<DOCNO>NCT00718692</DOCNO>
	<brief_summary>This trial design multi-centre , single-dose , exploratory dose-finding , open label trial evaluate safety efficacy Sym001 4-9 consecutive cohort . Subjects receive single IV dose Sym001 .</brief_summary>
	<brief_title>Open Label Trial Safety Efficacy Sym001 Treatment Immune Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Confirmed presence thrombocytopenia platelet count &lt; 30,000/mm3 predose visit . History isolate ITP RhDpositive serology . Previous treatment response first line therapy ITP Known clinical picture suggestive cause thrombocytopenia , especially systematic lupus erythematosus , antiphospholipid syndrome , Evans syndrome , immunodeficiency state , lymphoproliferative disorder , liver disease , ingestion drug quinidine/quinine , heparin sulfonamide hereditary thrombocytopenia confirm relevant laboratory finding . Suspected infection HIV , Hepatitis C , H. pylorus . Clinical splenomegaly History abnormal bone marrow examination . Ongoing haemorrhage correspond grade 3 4 WHO bleed scale . Underlying haemolytic condition History splenectomy . Subject pregnant , breast feeding intend become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>ITP</keyword>
</DOC>